OccuLogix to conduct FDA-requested study

By Elaine Rigoli

Tampa, Fla., June 12 - OccuLogix, Inc. said the Food and Drug Administration requested an additional RHEO study be performed prior to granting marketing approval.

The company recently completed a clinical trial using its RHEO system to treat the dry form of age-related macular degeneration.

Accordingly, the company said it expects to submit its application for an Investigational Device Exemption with a new protocol to the FDA within the next 60 days.

Details of the new study will be released when the IDE is filed and accepted by the FDA.

OccuLogix is a Toronto-based health care company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.